$TPST (TEMPEST THERAPEUTICS) — 8-K: Tempest secures exclusive option to license Senlang's CD7-targeted lentiviral in vivo CAR-T platform

The lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma. Early clinical observations at the highest evaluable dose show in vivo CAR-T generation and expansion, with no Grade 3 or higher cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome as of August 25, 2026. The option complements Tempest's CD7-targeted lipid nanoparticle in vivo CAR-T platform, planned to enter the clinic later this year.

The lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma. Early clinical observations at the highest evaluable dose show in vi